These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35994087)

  • 1. Structural and Mechanistic Evidence for Calcium Interacting Sites in the HIV Transmembrane Protein gp41 Involved in Membrane Fusion.
    Klug YA; Schwarzer R; Ravula T; Rotem E; Ramamoorthy A; Shai Y
    Biochemistry; 2022 Sep; 61(17):1915-1922. PubMed ID: 35994087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
    Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
    Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
    Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
    Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
    J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
    Liu S; Jiang S
    Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.
    Kesavardhana S; Varadarajan R
    J Virol; 2014 Sep; 88(17):9590-604. PubMed ID: 24920800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
    Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry.
    Wang X; Xiong W; Ma X; Wei M; Chen Y; Lu L; Debnath AK; Jiang S; Pan C
    PLoS One; 2012; 7(9):e44874. PubMed ID: 22970321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
    PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O; Sackett K; Shai Y
    J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
    He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
    J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.